Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02781584 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 220
- Enrollment target
NCT02781584 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 220 participants.
The verdict
NCT02781584, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 220 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety and tolerability of selonsertib, firsocostat, cilofexor, fenofibrate and/or Vascepa® in adults with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).
Interventions
- DRUG SEL
- DRUG FIR
- DRUG CILO
- DRUG FENO
- DRUG VAS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2016-06-13 |
| Est. Completion | 2020-12-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02781584
The ClinicalTrials.gov registry entry for NCT02781584 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which SEL is the first listed.
NCT02781584 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02781584 about?
NCT02781584 is a clinical study titled "Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)". The primary objective of this study is to evaluate the safety and tolerability of selonsertib, firsocostat, cilofexor, fenofibrate and/or Vascepa® in adults with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).
What is the current status of trial NCT02781584?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 220 participants. The study started on 2016-06-13. Estimated completion is 2020-12-17.
What interventions are being tested in trial NCT02781584?
The interventions under investigation include: SEL (DRUG), FIR (DRUG), CILO (DRUG), FENO (DRUG), VAS (DRUG).
Who is sponsoring clinical trial NCT02781584?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.